Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 8/20 | 0.54 |
| ▸ | SULT1A1 | P50225 | 4/20 | 0.54 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2552559 | 0.81 | APP (0.55) | APPMAPTKDM4ESMN1; SMN2POLB | |
| SCHEMBL14916683 | 0.78 | ALDH1A1 (0.58) | APPSULT1A1GPR35MAPTKDM4E | |
| SCHEMBL30405538 | 0.78 | ALDH1A1 (0.58) | APPSULT1A1GPR35MAPTKDM4E | |
| SCHEMBL14157073 | 0.77 | APP (0.68) | APPSULT1A1GPR35MAPTKDM4E | |
| SCHEMBL1289509 | 0.75 | ESR1 (0.51) | HPGDSKDM4ESMN1; SMN2RPS6KB2POLB | |
| SCHEMBL4352378 | 0.75 | HSD17B1 (0.67) | MAPTGAAHTTL3MBTL1DYRK1A | |
| SCHEMBL29377869 | 0.73 | GPR35 (0.52) | APPSULT1A1GPR35MAPTKDM4E | |
| SCHEMBL4746701 | 0.73 | GPR35 (0.52) | APPSULT1A1GPR35MAPTKDM4E | |
| SCHEMBL1179812 | 0.73 | SMN1; SMN2 (0.68) | APPSULT1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL27903671 | 0.72 | GPR35 (0.48) | APPSULT1A1GPR35MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110172051-B | IRE-1 alpha inhibitors | 复星弘创(苏州)医药科技有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-11337956-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2022-05-24 | — | — | US | disclosed |
| EP-3799870-A1 | IRE-1A INHIBITORS | Fosun Orinove Pharmatech, Inc. (CN) | 2021-04-07 | — | — | EP | disclosed |
| EP-3409276-B1 | IRE-1A INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2020-12-30 | — | — | EP | disclosed |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-10-17 | — | — | US | disclosed |
| US-10357475-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-07-23 | — | — | US | disclosed |
| EP-3409276-A1 | IRE-1A INHIBITORS | Fosun Orinove Pharmatech, Inc. (CN) | 2018-12-05 | — | — | EP | disclosed |
| EP-2555768-B1 | IRE-1 INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2018-08-29 | — | — | EP | disclosed |
| US-9867803-B2 | IRE-1α inhibitors | SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) | 2018-01-16 | — | — | US | disclosed |
| US-20170326104-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-11-16 | — | — | US | disclosed |
| US-9693992-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-9040714-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| CN-103079558-A | IRE-1 alpha inhibitors | MANNKIND CORP | 2013-05-01 | — | — | CN | disclosed |
| EP-2555768-A2 | IRE-1 INHIBITORS | MannKind Corporation (US) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011127070-A2 | IRE-1α INHIBITORS | MANNKIND CORPORATION (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141424-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | APP 2146/4885SULT1A1 2692/4885GPR35 4487/4885 |
| US-20170326104-A1 | IRE-1ALPHA INHIBITORS | ERN1, XBP1, ERN2 | APP 2146/4885SULT1A1 2692/4885GPR35 4487/4885 |
| US-11337956-B2 | IRE-1α inhibitors | XBP1, ERN1, ERN2 | APP 1427/4885SULT1A1 2700/4885GPR35 4518/4885 |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | ERN1, XBP1, ERN2 | APP 2146/4885SULT1A1 2692/4885GPR35 4487/4885 |
| US-10357475-B2 | IRE-1α inhibitors | XBP1, ERN1, ERN2 | APP 1427/4885SULT1A1 2700/4885GPR35 4518/4885 |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | APP 1860/4885SULT1A1 2577/4885GPR35 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.